EP1765365A4 - Compositions and methods ofr the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide - Google Patents

Compositions and methods ofr the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Info

Publication number
EP1765365A4
EP1765365A4 EP05786102A EP05786102A EP1765365A4 EP 1765365 A4 EP1765365 A4 EP 1765365A4 EP 05786102 A EP05786102 A EP 05786102A EP 05786102 A EP05786102 A EP 05786102A EP 1765365 A4 EP1765365 A4 EP 1765365A4
Authority
EP
European Patent Office
Prior art keywords
drugs
ofr
polysaccharide
delivery
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05786102A
Other languages
German (de)
French (fr)
Other versions
EP1765365A2 (en
Inventor
David Platt
Eliezer Zomer
Anatole Klyosov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Pharmaceuticals Inc
Original Assignee
Pro Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc
Publication of EP1765365A2 publication Critical patent/EP1765365A2/en
Publication of EP1765365A4 publication Critical patent/EP1765365A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP05786102A 2004-06-22 2005-06-21 Compositions and methods ofr the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide Withdrawn EP1765365A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58195804P 2004-06-22 2004-06-22
PCT/US2005/021827 WO2006002106A2 (en) 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Publications (2)

Publication Number Publication Date
EP1765365A2 EP1765365A2 (en) 2007-03-28
EP1765365A4 true EP1765365A4 (en) 2008-02-20

Family

ID=35782284

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05786102A Withdrawn EP1765365A4 (en) 2004-06-22 2005-06-21 Compositions and methods ofr the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Country Status (6)

Country Link
EP (1) EP1765365A4 (en)
JP (1) JP2008503583A (en)
CN (1) CN101267828A (en)
BR (1) BRPI0512394A (en)
CA (1) CA2570570A1 (en)
WO (1) WO2006002106A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101760758B1 (en) 2008-05-14 2017-07-24 애그리컬쳐 빅토리아 서비스 피티와이 엘티디 Use of angiogenin or angiogenin agonists for treating diseases and disorders
AU2013204721B2 (en) * 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
CZ302789B6 (en) 2009-11-25 2011-11-09 Zentiva, K. S. Method of increasing solubility of pharmaceutically active compounds and targeted (controlled) transport thereof into intestine
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
FR3022462B1 (en) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies ORAL COMPOSITION OF ANTI-TNFALPHA ANTIBODY

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773425A (en) * 1982-05-07 1998-06-30 Carrington Laboratories, Inc. Antineoplastic uses of aloe products
US5811410A (en) * 1989-09-21 1998-09-22 Hyal Pharmaceutical Corporation Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID
EP0958825A1 (en) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer
WO2001017377A1 (en) * 1999-09-06 2001-03-15 Beisel Guenther Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said
WO2002076474A1 (en) * 2001-03-27 2002-10-03 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
KR20040045795A (en) * 2002-11-25 2004-06-02 주식회사한국신약 Anti-cancer agent comprising polysaccharide obtained from mycelia of Phellinus linteus and mitomycine C

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020107222A1 (en) * 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773425A (en) * 1982-05-07 1998-06-30 Carrington Laboratories, Inc. Antineoplastic uses of aloe products
US5811410A (en) * 1989-09-21 1998-09-22 Hyal Pharmaceutical Corporation Method of administering of a hyaluronic acid and an NSAID to decrease side effects of the NSAID
EP0958825A1 (en) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer
WO2001017377A1 (en) * 1999-09-06 2001-03-15 Beisel Guenther Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said
WO2002076474A1 (en) * 2001-03-27 2002-10-03 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
KR20040045795A (en) * 2002-11-25 2004-06-02 주식회사한국신약 Anti-cancer agent comprising polysaccharide obtained from mycelia of Phellinus linteus and mitomycine C

Also Published As

Publication number Publication date
BRPI0512394A (en) 2008-03-11
CN101267828A (en) 2008-09-17
CA2570570A1 (en) 2006-01-05
WO2006002106A3 (en) 2006-10-19
EP1765365A2 (en) 2007-03-28
JP2008503583A (en) 2008-02-07
WO2006002106A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
EP1909780A4 (en) Anti-tubercular drugs: compositions and methods
IL181734A (en) Polymorph i of sorafenib tosylate, pharmaceutical compositions comprising it and its use in the manufacture of medicaments
IL203915A (en) 2-benzylphenyl-6-hydroxymethyl-tetrahydro-2h-pyran-3,4,5-triol derivatives and pharmaceutical compositions comprising the same
IL194699A (en) Tetrahydropteridines, compositions comprising them and use thereof in the preparation of medicaments
IL242883B (en) Arylamino- and heteroarylamino-substituted dioxoazolines and pharmaceutical compositions comprising them
IL195488A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL194707A (en) Synergistic anticancer combination of taxanes and 13-deoxyanthracyclines and a pharmaceutical composition comprising the same
IL190292A (en) Pyridopyrimidinone derivatives and pharmaceutical compositions comprising them
HK1112427A1 (en) Drug delivery compositions and related methods
EP1962906A4 (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
IL231576A (en) Adamantyl-acetamide derivatives, pharmaceutical compositions comprising same and use thereof in the manufacture of medicaments
IL184065A (en) Tetrahydroquinoline analogues, uses thereof in the preparation of medicaments and pharmaceutical compositions comprising same
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
EP1857489A4 (en) Microparticle and pharmaceutical composition
IL206952A (en) Aminodihydrothiazine derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
EP2056835A4 (en) Pharmaceutical compositions and uses thereof
EP1890677A4 (en) Pharmaceutical compositions and use thereof
IL187997A0 (en) Indane derivatives and pharmaceutical compositions containing the same
IL177073A0 (en) Hydroxy-6-heteroarylphenanthridine derivatives and pharmaceutical compositions containing the same
IL193164A0 (en) Polymeric conjugates of 7-ethyl-10-hydroxycamptothecin and pharmaceutical compositions containing the same
IL197107A0 (en) Pharmaceutical compositions including vitamin d and corticosteriod
IL178067A0 (en) Pharmaceutical dosage forms and compositions
IL183986A0 (en) Pharmaceutical compounds and compositions
IL193211A (en) Indazole-heteroaryl derivatives and pharmaceutical compositions comprising them
EP1911761A4 (en) Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions and the use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061215

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/50 20060101ALI20080117BHEP

Ipc: A61K 38/00 20060101ALI20080117BHEP

Ipc: A61K 33/24 20060101ALI20080117BHEP

Ipc: A61K 33/00 20060101ALI20080117BHEP

Ipc: A61P 35/00 20060101ALI20080117BHEP

Ipc: A61K 31/513 20060101ALI20080117BHEP

Ipc: A61K 31/337 20060101ALI20080117BHEP

Ipc: A61K 31/715 20060101AFI20070110BHEP

17Q First examination report despatched

Effective date: 20090605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090916